- Health Canada approved Novartis’ Vanrafia (atrasentan) to reduce proteinuria in adults with IgA nephropathy (IgAN) at risk of rapid disease progression.
- Vanrafia is indicated for patients with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g, helping address progressive kidney damage.
- The approval is based on the Phase III ALIGN trial, where Vanrafia significantly reduced 24-hour proteinuria at Week 36 versus placebo.
- The therapy offers a new treatment option for IgAN, an autoimmune kidney disease that can lead to chronic kidney damage and kidney failure.
Takeaways
Health Canada’s approval of Novartis’ Vanrafia (atrasentan) creates Canada’s first endothelin receptor antagonist–based therapy specifically for IgA nephropathy, giving clinicians a new, indication-specific option to reduce proteinuria and slow progression in patients with UPCR ≥1.5 g/g.
Source: Novartis
